Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emily Hayes

San Francisco, CA
Emily Hayes is a writer/editor with over 20 years’ experience in medical journalism, including magazines for specialist clinicians, government health publications, business newswires and pharma trade press.  Her educational background lies in journalism and political science. Emily has dual citizenship and has experience working in the UK and US. Since 2008, she has been a senior writer on staff with “The Pink Sheet,” working out of her home base in biopharma hub San Francisco. She enjoys covering drug development, with special areas of focus in cancer, particularly immunotherapy, and cardiology/metabolics. She covers major scientific meetings regularly, including the American Society of Clinical Oncology, and appreciates interactions with key opinion leaders while interpreting drug trial results. In her free time, she is a professional jazz/blues/country vocalist.
Advertisement
Set Alert for Articles By Emily Hayes

Latest From Emily Hayes

What The New US Cholesterol Treatment Guidelines Mean For Esperion

Guidelines place high emphasis on low cost, but also outcomes data. Esperion plans to file bempedioc acid next year, but outcomes data won’t be available until 2022.

Cardiovascular Cost Effectiveness

Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer

PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.

Clinical Trials Cancer

New US Cholesterol Guidelines Hit PCSK9s Hard On Pricing, Value

Already outdated? The latest ACC/AHA guidelines say at mid-2018 list prices, PCSK9 injectables are of low value, but the costs have plummeted since then.

Cost Effectiveness Cardiovascular

AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure

Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.

Research & Development Cardiovascular

Buoyed By Phase III Rosacea Success, Foamix Plans Commercial Transition

Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical minocycline foam on its own.

 

Research & Development Dermatology

Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds

In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.

Cancer BioPharmaceutical
See All
Advertisement
UsernamePublicRestriction

Register